Selected article for: "cell transplantation and combined immunodeficiency"
Author: Delavari, Samaneh; Abolhassani, Hassan; Abolnezhadian, Farhad; Babaha, Fateme; Iranparast, Sara; Ahanchian, Hamid; Moazzen, Nasrin; Nabavi, Mohammad; Arshi, Saba; Fallahpour, Morteza; Bemanian, Mohammad Hassan; Shokri, Sima; Momen, Tooba; Sadeghi-Shabestari, Mahnaz; Molatefi, Rasol; Shirkani, Afshin; Vosughimotlagh, Ahmad; Safarirad, Molood; Sharifzadeh, Meisam; Pashangzadeh, Salar; Salami, Fereshte; Shirmast, Paniz; Rezaei, Arezou; Moeini Shad, Tannaz; Mohraz, Minoo; Rezaei, Nima; Hammarström, Lennart; Yazdani, Reza; Aghamohamamdi, Asghar
Title: Impact of SARS-CoV-2 Pandemic on Patients with Primary Immunodeficiency
  • Cord-id: 8h3kdxv9
  • Document date: 2020_12_1
    • ID: 8h3kdxv9
    Snippet: Although it is estimated that COVID-19 life-threatening conditions may be diagnosed in less than 1:1000 infected individuals below the age of 50, but the real impact of this pandemic on pediatric patients with different types of primary immunodeficiency (PID) is not elucidated. The current prospective study on a national registry of PID patients showed that with only 1.23 folds higher incidence of infections, these patients present a 10-folds higher mortality rate compared to population mainly i
    Document: Although it is estimated that COVID-19 life-threatening conditions may be diagnosed in less than 1:1000 infected individuals below the age of 50, but the real impact of this pandemic on pediatric patients with different types of primary immunodeficiency (PID) is not elucidated. The current prospective study on a national registry of PID patients showed that with only 1.23 folds higher incidence of infections, these patients present a 10-folds higher mortality rate compared to population mainly in patients with combined immunodeficiency and immune dysregulation. Therefore, further management modalities against COVID-19 should be considered to improve the survival rate in these two PID entities using hematopoietic stem cell transplantation and immunomodulatory agents. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10875-020-00928-x.

    Search related documents:
    Co phrase search for related documents
    • access data and acute phase: 1, 2
    • access data and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • access data and adolescent child: 1
    • access funding and acute respiratory syndrome: 1, 2, 3
    • activator signal transducer and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5
    • activator signal transducer and acute ards respiratory distress syndrome cause: 1
    • activator signal transducer and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • activator signal transducer and adaptive immunity: 1, 2
    • acute ards respiratory distress syndrome and adaptive immunity: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and adolescent child: 1
    • acute ards respiratory distress syndrome and liver failure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute ards respiratory distress syndrome and low frequency: 1
    • acute ards respiratory distress syndrome cause and liver failure: 1
    • acute phase and adaptive immunity: 1, 2, 3, 4, 5, 6, 7
    • acute phase and liver failure: 1, 2, 3, 4, 5
    • acute phase and low frequency: 1, 2
    • acute respiratory syndrome and adaptive immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and adolescent child: 1, 2, 3, 4, 5
    • acute respiratory syndrome and liver failure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25